Clinical experience of TB in patients treated with anti-TNF-α

Int J Tuberc Lung Dis. 2021 Oct 1;25(10):866-868. doi: 10.5588/ijtld.21.0166.

Authors

M Arenas-Miras¹, F Sánchez-Martínez¹, N Jové-Caballé¹, J Villar-García¹, I López-Montesinos¹, S Grau², N Carballo², H Knobel-Freud¹, J P Horcajada¹

Affiliations

¹ Infectious Diseases Department, Institut Hospital del Mar d´Investigacions Mèdiques (IMIM), Hospital del Mar, Barcelona, Spain.
² Pharmacy Department, Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d´Investigacions Mèdiques (IMIM), Hospital del Mar, Barcelona, Spain.

PMID: 34615586
DOI: 10.5588/ijtld.21.0166

No abstract available

MeSH terms

Adalimumab / therapeutic use
Humans
Infliximab / therapeutic use
Tuberculosis / drug therapy*
Tumor Necrosis Factor Inhibitors* / therapeutic use

Substances

Tumor Necrosis Factor Inhibitors
Infliximab
Adalimumab